Skip to main content

Advertisement

Table 1 Patient demographics and clinical characteristics

From: Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma

Variables SSc Patients Topo-I negative (N = 12) Topo-I positive (N = 15) P value§
Age (years)* 51.3 ± 9.6 55.1 ± 7.4 48.2 ± 10.3 .093
Female 21 (78) 9 (75) 12 (80) .557
Race
 White 22 (81) 9 (75) 13 (87) .338
 Black 5 (19) 3 (25) 2 (13)
Smoking status
 Never 16 (62) 9 (82) 7 (47) .174
 Past 1 (4) 0 (0) 1 (7)
 Current 9 (34) 2 (18) 7 (47)
Diffuse SSc skin type 15 (56) 5 (42) 10 (67) .182
mRSS* (range 0–51) 7 ± 8 5 ± 9 9 ± 7 .037
SSc duration
 RP onset*, years 11.1 ± 7.8 11.2 ± 7.3 10.9 ± 8.5 .516
 1st non-RP symptom*, years 10.2 ± 7.1 11.0 ± 7.2 9.6 ± 7.3 .792
Lung severity score* (range 0–4) 1.2 ± 1.3 0.9 ± 1.5 1.5 ± 1.1 .168
FVC* (% predicted) 77.9 ± 14.7 81.4 ± 19.8 77.07 ± 11.1 .106
DLCO* (% predicted) 75.3 ± 16.6 83.8 ± 15.7 71.3 ± 17.3 .051
ILD 11 (46) 1 (10) 10 (71) .005
eRVSP* 28.8 ± 12.5 32.5 ± 17.5 25.9 ± 5.9 .522
Autoantibody status
 ACA 3 (11) 3 (25) 0 (0) .075
 Anti-RNA-polymerase III 5 (21) 3 (25) 1 (8) .295
Immunosuppression (current) 11 (41) 4 (33) 7 (47) .381
  1. All values are given as number (%) unless otherwise specified. Frequencies (%) are calculated based on available data. SSc disease duration was calculated at the time of serum sampling from the onset of RP or from the first non-RP symptom. Lung severity score is reported as previously defined by Medsger et al. [29]
  2. ACA anticentromere antibody, DLCO, diffusion capacity of lung for carbon monoxide, eRVSP right ventricular systolic pressure estimated by echocardiography, FVC forced vital capacity, ILD interstitial restrictive lung disease, mRSS modified Rodnan skin score, RP Raynaud’s phenomenon, SSc systemic sclerosis
  3. *Mean ± SD
  4. The presence of ILD was defined by presence of fibrosis on computed tomography of the chest (CT chest was available in 10 topo-I-negative and 14 topo-I-positive subjects)
  5. Use of immunosuppressants includes cyclophosphamide, mycophenolate, methotrexate, or prednisone
  6. § P values were determined by Fisher’s exact test, Pearson chi-square, or the Wilcoxon rank-sum test, as appropriate